Back to results
US 2026/0007672 A1Published application
Inhibitors of mptp
AssigneeNRG Therapeutics Ltd
InventorsNeil MILLER, Gilles OUVRY, Richard RUTTER, Tammy LADDUWAHETTY, Christopher THOMSON, Jan KULAGOWSKI, Michael ROWLEY, Andrew TUFFNELL, Gabriel NEGOITA-GIRAS, Mark STEWART, Rachel ARMSTRONG, Susan BOYD
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula (I), and related aspects.
Claims23
A compound according to formula (I):
- wherein:
- R1 is H;
- R2 is H, halo, C1-4alkyl, C1-4haloalkyl;
- C1-4alkoxy, C1-4haloalkoxy or C0-4alkylene(OH);
- R3 is H, halo or C1-4alkyl;
- R4 is H, halo or C1-4alkyl;
- R5 is halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C1-6haloalkoxy, C2-6alkenyl, C2-6haloalkenyl, C0-6alkylene(C3-6cycloalkyl), C0-6alkylene(OH);
- or R4 and R5 together with the carbon atom to which they are attached form a C5-11 spiro carbocyclyl, 4 to 7 membered heterocycle or C3-6cycloalkyl wherein said spiro carbocyclyl, heterocycloalkyl or cycloalkyl may be optionally substituted by one or more groups selected from C1-3alkyl, C1-3haloalkyl and halo;
- R6 is H or C1-4alkyl;
- R7 is H, halo, C1-4alkyl, C1-4haloalkyl, C1-4alkoxy or C1-4haloalkoxy;
- A is selected from the group consisting of unsubstituted phenyl and (A1) to (A6):
- wherein:
- A1A is halo, C1-6alkyl, or C1-6alkoxy;
- and
- A1B is H or halo;
- and
- B is selected from the group consisting of (B1) to (B3) and (B5) to (B9):
- wherein:
- B1A is H, halo, or C1-6alkyl;
- and
- B2A is H, halo, or C1-6alkyl;
- or a salt and/or solvate thereof,
- and provided that the compound according to formula (I) or salt and/or solvate thereof is not N-((1-benzylcyclobutyl)methyl)-6-hydroxypyrazine-2-carboxamide:
- or a salt and/or solvate thereof.
21 more elements
Dependencies are inferred from the claim text.